Hosted on MSN11mon
New Blood Thinners Will Prevent Blood Clots Without Causing BleedingMilvexian targets the activated, or clot-initiating, form of factor XI, called factor XIa. Harvard’s Gibson is leading one of the trials. Also in the mix is Anthos Therapeutics, a startup ...
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...
Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, Mass.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results